Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Susan P. Lees-Miller"'
Publikováno v:
Genome Instability & Disease
DNA-dependent protein kinase catalytic subunit DNA-PKcs/PRKDC is the largest serine/threonine protein kinase of the phosphatidyl inositol 3-kinase-like protein kinase (PIKK) family and is the most highly expressed PIKK in human cells. With its DNA-bi
Autor:
Alan E. Tomkinson, Susan Fishbain, Susan P. Lees-Miller, Yuan He, Siyu Chen, Tasmin Naila, Annie Wang, Linda Lee
Publikováno v:
Nature
DNA double-strand breaks (DSBs) are a highly cytotoxic form of DNA damage and the incorrect repair of DSBs is linked to carcinogenesis1,2. The conserved error-prone non-homologous end joining (NHEJ) pathway has a key role in determining the effects o
Autor:
John B. McIntyre, Michelle Dean, Martin Köbel, Tien Phan, Emeka K. Enwere, Elizabeth N. Kornaga, Corinne M. Doll, Prafull Ghatage, Angela Chan, Kevin Martell, Susan P. Lees-Miller
Publikováno v:
Gynecologic Oncology. 158:776-784
Purpose This study aimed to describe the prognostic value of PI3K/AKT pathway mutations in a large cohort of patients with cervical cancer. Experimental design Patients with pre-treatment archival specimens, diagnosed with FIGO stages IB-IVA cervical
Autor:
Greydon Arthur, Siddhartha Goutam, Suraj Radhamani, Anthony Bolyos, L. Petersen, Ruiqiong Ye, D. Gwyn Bebb, Susan P. Lees-Miller, Pinaki Bose, Nicholas Jette
Publikováno v:
British Journal of Cancer
Background Up to 40% of lung adenocarcinoma have been reported to lack ataxia-telangiectasia mutated (ATM) protein expression. We asked whether ATM-deficient lung cancer cell lines are sensitive to poly-ADP ribose polymerase (PARP) inhibitors and det
Autor:
Bruno Sangro, Christopher McCoy, Puri Fortes, Fernando Moreno-Herrero, Linda Lee, Sara de Bragança, Susan P. Lees-Miller, Oscar Llorca, Juan Pablo Unfried, Clara Aicart-Ramos, Gareth J. Williams, Laura Prats-Mari, Eva María Martín-Cuevas, Raquel Arribas-Bosacoma, Stefano Caruso, Angel Rivera-Calzada, Jessica Zucman-Rossi, Nerea Razquin, Mikel Marin-Baquero
Publikováno v:
Cancer Res
Digital.CSIC. Repositorio Institucional del CSIC
instname
Cancer Research
Digital.CSIC. Repositorio Institucional del CSIC
instname
Cancer Research
[Abstract] Long noncoding RNAs (lncRNA) are emerging as key players in cancer as parts of poorly understood molecular mechanisms. Here, we investigated lncRNAs that play a role in hepatocellular carcinoma (HCC) and identified NIHCOLE, a novel lncRNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cae90efa1b6096c29d3ead27e258865
https://europepmc.org/articles/PMC8488005/
https://europepmc.org/articles/PMC8488005/
Autor:
John A. Tainer, James P. Lees-Miller, Panagiotis Katsonis, Dave W. Anderson, Olivier Lichtarge, Albino Bacolla, Katheryn Meek, Susan E. Tsutakawa, Susan P. Lees-Miller, Michal Hammel, Alexander Cobban
Publikováno v:
Progress in biophysics and molecular biology. 163
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is a key member of the phosphatidylinositol-3 kinase-like (PIKK) family of protein kinases with critical roles in DNA-double strand break repair, transcription, metastasis, mitosis, RNA proces
Autor:
Edward Bartlett, Pauline Douglas, Alexander Cobban, Nicole P. Jenkins, Ruiqiong Ye, Jonathan Roveredo, Arminja N. Kettenbach, Suraj Radhamani, Susan P. Lees-Miller
Publikováno v:
Molecular and Cellular Biology
The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) has well-established roles in DNA double-strand break repair, and recently, nonrepair functions have also been reported. To better understand its cellular functions, we deleted DNA-PKcs fr
Autor:
Pinaki Bose, Siddhartha Goutam, Tarek A. Bismar, Nicholas Jette, Suraj Radhamani, Greydon Arthur, Yaping Yu, Steven Yip, Ruiqiong Ye, Michael Paul Kolinsky, Susan P. Lees-Miller, Mehul Kumar
BackgroundThe ataxia telangiectasia mutated (ATM) protein kinase is mutated in several human cancers, presenting potential opportunities for targeted cancer therapy. We previously reported that the poly-ADP ribose polymerase (PARP) inhibitor olaparib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7fa4d65666885c32c1bceb1bdab8b7
https://doi.org/10.1101/2020.03.13.991166
https://doi.org/10.1101/2020.03.13.991166
Autor:
Pinaki Bose, Siddhartha Goutam, Michael Paul Kolinsky, Steven Yip, Nicholas Jette, Mehul Kumar, Greydon Arthur, Suraj Radhamani, Susan P. Lees-Miller, Gareth J. Williams
Publikováno v:
Cancers
Cancers, Vol 12, Iss 3, p 687 (2020)
Cancers, Vol 12, Iss 3, p 687 (2020)
Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, with many more potential applications under study and in cli
Autor:
Theodora A. Koulis, Susan P. Lees-Miller, Anthony M. Magliocco, Robyn Banerjee, Elizabeth N. Kornaga, Tien Phan, Prafull Ghatage, Corinne M. Doll
Publikováno v:
Clinical and Translational Radiation Oncology
Clinical and Translational Radiation Oncology, Vol 4, Iss C, Pp 51-56 (2017)
Clinical and Translational Radiation Oncology, Vol 4, Iss C, Pp 51-56 (2017)
Introduction: Anemia has long been associated with poor prognosis in patients with cervical cancer. Recently, additional hematologic parameters have emerged as potential indicators of worse outcome in this patient group. In a cohort of cervical cance